Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.55 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.49 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.49 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440123 | 1.00 | TDP1 (0.73) | TDP1KDM4EPOLBAPEX1MEN1 | |
| SCHEMBL7532175 | 0.87 | POLB (0.68) | TDP1KDM4EPOLBAPEX1MEN1 | |
| SCHEMBL8689243 | 0.87 | TDP1 (0.68) | TDP1KDM4EPOLBAPEX1MEN1 | |
| SCHEMBL15647380 | 0.81 | KMT2A (0.67) | TDP1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL16655841 | 0.80 | KDM4E (0.68) | TDP1KDM4EPOLBAPEX1MEN1 | |
| SCHEMBL30894835 | 0.80 | MAPT (0.60) | TDP1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL9416712 | 0.80 | MAPT (0.60) | TDP1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL111313 | 0.79 | ALDH1A1 (0.76) | TDP1KDM4EPOLBAPEX1MEN1 | |
| SCHEMBL7544693 | 0.79 | KDM4E (0.59) | TDP1KDM4EPOLBAPEX1MEN1 | |
| SCHEMBL582448 | 0.79 | KDM4E (0.67) | TDP1KDM4EPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107162928-B | Halogenated analogs of anti-fibrotic agents | 塞尔塔医疗有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3045170-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| EP-3045170-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| EP-3045170-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2016-07-20 | — | — | EP | disclosed |
| EP-3045170-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2016-07-20 | — | — | EP | disclosed |
| EP-2220028-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2016-03-09 | — | — | EP | disclosed |
| EP-2220028-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2016-03-09 | — | — | EP | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
| EP-2220028-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2010-08-25 | — | — | EP | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| WO-2009079692-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009079692-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2009-07-02 | — | — | WO | disclosed |
| EP-2035369-A1 | THERAPEUTIC COMPOUNDS | Fibrotech Therapeutics PTY LTD (AU) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | TDP1 3685/4885KDM4E 1709/4885POLB 3843/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | TDP1 2890/4885KDM4E 1397/4885POLB 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.